CFT8634, a BRD9 BiDAC™ Degrader, is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic when Combined with Pomalidomide or Dexamethasone
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined